Semi-Annual Report — FY2026 H1
What Kyowa Kirin Co.,Ltd. reported for the period from 2026-01-01 to 2026-12-31.
Filed 2026-08-03View the original on EDINET
How much it says
53Typical
What moved here
9named for the first time
Its own wording
49terms
Which filing this is
37/ 37newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the current interim consolidated accounting period, revenue, core operating profit, and interim profit increased year on year, with the impact of foreign exchange and other factors also described. Orchard Therapeutics Limited resolved to dissolve and liquidate in July 2025 and completed its liquidation in January 2026, and was therefore excluded from the scope of consolidation.
Komori's summary of this document, not the document's own words.53Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 34 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
84
Very detailed
54
Typical
48
Typical
62
Detailed
0
Almost nothing
68
Detailed
0
Almost nothing
62
Detailed
69
Detailed
31
Thin
100
Very detailed
R&D spend463億円Money spent making new things.
Cash left over638億円Cash from the business, less what went into equipment.
Spent on equipment186億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.